Journal
BIOMARKERS
Volume 18, Issue 8, Pages 721-725Publisher
INFORMA HEALTHCARE
DOI: 10.3109/1354750X.2013.853839
Keywords
BCL6B; biomarker; gastric cancer; plasma DNA; promoter methylation
Categories
Funding
- National Basic Research Program of China (973 Program) [2010CB529305]
- National Natural Science Foundation of China [81172346]
- Group Research Scheme CUHK [3110043]
Ask authors/readers for more resources
We previously showed that BCL6B acts as a tumor suppressor in gastric cancer and up to 66% gastric cancer patients have promoter hypermethylation in tumor tissues. We aimed to evaluate the feasibility of detecting BCL6B methylation in plasma DNA as a potential biomarker for gastric cancer. Hypermethylation of the CpG islands in BCL6B promoter was detected in 42.5% (17/40) plasma DNA samples from gastric cancer patients, while no methylation was found in the plasma DNA of healthy controls (p<0.001). BCL6B methylation may serve as a novel potential non-invasive plasma biomarker for the detection of gastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
